This trial is evaluating whether Pembrolizumab will improve 3 primary outcomes and 13 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Up to approximately 29 months.
This trial requires 793 total participants across 2 different treatment groups
This trial involves 2 different treatments. Pembrolizumab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
A range of treatment options exist for men with [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Physicians will need to do a good job of balancing the risks and benefits of the different treatments to ensure that the patient's best chance of cancer curability will prevail.
There is evidence that sex hormones can affect [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) incidence. Some studies show it is more common in males with enlarged prostates. And there is also an age-related increase in incidence of this cancer, especially in men over the age of 65. Some of these factors may be the cause of prostatic cancer.
As there are no clear signs of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer), biopsy is likely to be the first step. Screening men for serum prostate specific antigen (PSA) may help to detect a small early cancer as it has a slightly higher percentage in detecting prostate cancer than serum PSA. It is more common for a large cancer with the potential for metastasis to cause symptoms of BPH. Screening men may also want to consider a baseline PSA to check for a change in their baseline PSA levels. Screening is not a primary choice for men with an elevated risk of prostate cancer only a referral for biopsy.
Almost 200,000 men and women in the United States were diagnosed with prostate cancer yearly. The proportion of younger men with prostate cancer continues to increase.
Prostate cancer, though an uncommon disease, is an important health concern for all men as the disease progressively worsens. Treatment is commonly complex and involves both radical curative procedures and non-curative treatment that provides relief from symptoms and delays the onset of and/or slows the progression of prostate cancer. The American Cancer Society estimates that there will be 233,680 new cases of prostate cancer and 68,740 deaths from prostate cancer in the USA in 2011. In contrast to this, prostate cancer has the lowest survival rate among all tumours in the male population, with 10-year survival rates of 67.5% in Canada, 43.5% in the UK, 29.5% in Sweden, and a 28.
Although there is no evidence as yet that prostate cancer can be cured, prostate cancer is highly treatable. Treatment options are improving and some symptoms can be minimized.
The most effective strategy may be in early stages of prostate cancer. The role of chemotherapy remains unresolved; however, and a combination of chemotherapy and radiation therapies may be the next level of treatment for localized prostate cancer.
The majority of patients use pembrolizumab in combination with other treatments. Nevertheless, further studies are needed to identify the most appropriate patients for this treatment.
Current research shows that [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) cells are constantly evolving and rearranging their receptors and other proteins to enable them to survive in our bodies. To that end, the prostate cancers have developed a ‘self’ immune system to ensure their own growth. It is for this reason that the immune system can no longer destroy the cancer cells but needs to control their growth. A new research line into the immune system's mechanisms of regulating prostate cancer growth. Prostate Cancer Suppressors. Gene Therapy. Prostate Cancer Therapeutics.
Pembrolizumab has been shown to be an effective therapeutic option in advanced or metastatic castration-resistant disease. The efficacy and safety of pembrolizumab in men with mCRPC were similar to those reported for the treatment of mCRPC with chemotherapy (chemoradiation). Findings from a recent study provide valuable support for the inclusion of pembrolizumab in the treatment algorithm for patients with mCRPC.
Survival probability decreased in the last decade, because the mortality from prostate cancer increased and the cause of death shifted from the prostate cancer, to the heart. Most prostate cancer deaths occurred during and/or after prostate cancer treatment, which usually affects patients with good prognosis.
Pembrolizumab is effective in the treatment of unresectable locally advanced or metastatic adenocarcinoma. In patients with mCRC, treatment with pembrolizumab leads to a short-term response at least in the majority of patients. However, OS rates remain low.